The Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta is uniquely positioned to leverage the vast knowledge and capabilities in Atlanta through collaborative relationships with Emory University School of Medicine, Winship Cancer Institute at Emory University, Georgia Institute of Technology, Morehouse School of Medicine and the Centers for Disease Control and Prevention (CDC). Working together, we continuously seek cures for the most challenging childhood oncologic and hematologic conditions.
As one of the most active institutions in the country in terms of pediatric clinical trial enrollment, Children’s offers patients access to more than 340 clinical studies available for patients, 28 Aflac investigator-initiated clinical trials, and over 675 study enrollments in 2022. We have some of the most novel diagnostic. and treatment options in the country, through our clinical research program. Our physicians participate—and often hold leadership roles—in all of the major national collaborative research consortia geared toward the early clinical development of promising therapies for cancer and blood disorders, including:
- Children’s Oncology Group (COG), including the Phase 1/Pilot Consortium (one of 20 centers nationwide)
- New Approaches to Neuroblastoma Therapy (NANT)
- Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL)
- Pediatric Blood and Marrow Transplant Consortium (PBMTC)
- Sickle Cell Clinical Research Network through the National Institutes of Health (NIH)
- Excellence in Hemoglobinopathies Award Program through the NIH
- Childhood Cancer Survivor Study
- Pediatric Brain Tumor Consortium (PBTC) (one of 15 centers nationwide)
Our goal is to provide an open clinical trial for every child we treat, making innovative care accessible to our patients who need it most. We also serve as a referral center for patients from across Georgia and throughout the U.S. who might not otherwise have access to Phase 1 and 2 trials.
Cancer and Blood Disorders Research News
Children’s Opens First Clinical Trial For New Therapy Targeting Leukemia
The trial aims to establish a safe dose of MRX-2843 for the treatment of acute leukemia
Children’s Now Offering Y90 Radioembolization for Pediatric Patients with Liver Cancer
Children’s is one of only a few pediatric centers around the county to offer this treatment
Cancer Precision Medicine Program Yields Impactful Results
Study shows most children with resistant cancer receive more precise clinical care through the Precision Medicine Program.
Abatacept Now FDA-Approved for Children Undergoing Unrelated Donor BMT
Tested and now available at Children’s, abatacept may lessen racial disparities.
FDA Approves Sickle-Slowing Drug
Tested at Children’s, a new drug targeting the underlying cause of sickle cell disease was recently approved by the FDA for patients ages 4 and older.
Children’s receives $20 million from Peach Bowl, Inc. to fight childhood cancer.
The overall goal of this generous Peach Bowl LegACy Fund is to help ensure that high-priority new treatment options can be tested, eventually leading to additional treatment options for our children.READ MORE
Emory University Department of Pediatrics Ranks No. 1 Again for NIH Research Grants
Emory’s Department of Pediatrics ranked No. 1 for federal research dollars from the National Institutes of Health (NIH) in 2022. Our partnership with Emory facilitates the leading-edge pediatric research, training and innovation that can lead to better outcomes.read more